For the benefit of our new readers: Reslizumab is a humanized monoclonal antibody against human interleukin-5. Reslizumab binds specifically to IL 5. This treatment is administered intravenously every four weeks and is mainly used in patients with severe brittle atopic eosinophilic asthma/ level 1 COPD/ Job syndrome.
In 2018 I was diagnosed with all three, the basic idea is that my body fights itself by producing more white blood cell (IL-5), this results in internal swelling in an attempt to protect itself; ordinarily this would be a positive reaction, however my body reacts in this way even when there is nothing to fight.
The one area of concentration for the internal swelling are my lungs, this can be fatal and last year I went into respiratory arrest, caused by excessive swelling in the airways.
One way to combat this is to introduce an antibody to bind the eosinophils and IL-5. For seven months I was receiving treatment, with the aim of reducing exacerbation and increasing lung capacity.
Unfortunately, although the exacerbation had reduced, my lung capacity continued to decrease therefore the decision was taken to take me off the treatment plan.
I have been off the treatment for six weeks now, so my body at this point will have no antibodies in the blood stream, leaving my body to continue its same complications
I feel in myself my chest has adopted a new normal level, my peak flows have dropped and I have become reliant of nebulisers, its slowly becoming a struggle to walk at speed, carry things whilst walking, and other light activities I managed whilst on the treatment.
My pains have returned, the lack of oxygen causing headaches, and constant tiredness and reduced level of ability have began to take hold.
I’ll keep you posted, as always; thank you for your time and if you have questions or remarks please feel welcome to leave comments and share the blogs if you enjoyed it.
Take a breath,